FDA Grants Coredio Breakthrough Designation for AI Platform Bringing Advanced Heart Failure Assessment Beyond the Hospital

Key Takeaways

• FDA granted Breakthrough Device Designation to Coredio’s CPSE platform.
• CPSE uses smartwatches and BP cuffs to estimate catheterization‑grade hemodynamics.
• Platform targets post‑discharge heart‑failure monitoring, aiming to reduce readmissions.
• Physics‑based digital twin combined with AI provides four key cardiac parameters.
• Accelerated 510(k) pathway could bring SaMD to market within years.

Pulse Analysis

Heart failure remains the most expensive chronic condition in the United States, affecting over 6.7 million adults and driving frequent hospitalizations. Traditional monitoring relies on intermittent echocardiograms, invasive catheterizations, or implantable sensors—tools that are either costly, limited to clinical settings, or reserved for high‑risk patients. Consequently, clinicians lose visibility during the vulnerable post‑discharge period, when patients are most prone to decompensation. The industry has been searching for scalable, low‑cost solutions that can deliver continuous, high‑fidelity cardiac data without adding procedural risk.

Coredio’s CPSE tackles this gap by fusing a physics‑based digital twin of an individual’s cardiovascular system with machine‑learning models trained on proprietary clinical datasets. The platform ingests signals from widely owned consumer wearables and standard blood‑pressure cuffs, translating them into four hemodynamic parameters that mirror invasive catheter measurements. This approach leverages the ubiquity of smartwatches to provide clinicians with real‑time, quantitative insights into left‑ventricular end‑diastolic pressure, central venous pressure, systemic vascular resistance, and cardiac index—all under physician supervision. The FDA’s Breakthrough Device Designation underscores the novelty and potential clinical impact of this non‑invasive methodology.

If CPSE secures clearance, it could reshape heart‑failure management by enabling earlier interventions, reducing emergency visits, and lowering overall care costs. Payers may view the technology as a cost‑saving alternative to readmission penalties, while hospitals could integrate it into transitional‑care programs to improve outcomes. However, adoption will hinge on clinician trust in AI‑derived metrics, reimbursement pathways, and the ability to seamlessly integrate data into electronic health records. Successful navigation of these hurdles could position Coredio as a leader in the emerging market for AI‑driven, wearable‑based cardiovascular diagnostics.